PRX 106

Drug Profile

PRX 106

Alternative Names: Anti-TNF therapeutic - Protalix Biotherapeutics; Anti-tumour necrosis factor therapeutic - Protalix Biotherapeutics; OPRX 106; pr-anti-TNF; PRX-106

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protalix Biotherapeutics
  • Developer Protalix BioTherapeutics
  • Class Recombinant fusion proteins
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 10 stimulants; Regulatory T-lymphocyte stimulants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammatory bowel diseases

Highest Development Phases

  • Phase II Ulcerative colitis
  • Preclinical Inflammatory bowel diseases; Non-alcoholic steatohepatitis
  • No development reported Autoimmune disorders; Crohn's disease; Fatty liver; Hepatitis; Rheumatoid arthritis

Most Recent Events

  • 05 Jun 2018 Safety and efficacy results from final analysis of phase II trial in Ulcerative colitis released by Protalix BioTherapeutics
  • 02 Jun 2018 Efficacy and Immunogenicity data from a phase IIa trial in Ulcerative Colitis presented at the Digestive Disease Week 2018 (DDW-2018)
  • 28 May 2018 No recent reports of development identified for preclinical development in Fatty liver in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top